Table 3.
SUCRA § values for efficacy and safety of triple FDCs according to the sensitivity analysis performed on the Bayesian network.
| Combinations | Efficacy | Safety | ||||||
|---|---|---|---|---|---|---|---|---|
| Risk of Moderate or Severe AECOPD | Change in Trough FEV1 | Change in TDI | Change in SGRQ | Risk of Total SAEs | Risk of CV SAEs | Risk of Pneumonia | Risk of All-Cause Mortality | |
| BDP/FOR/GLY 200/12/25 µg BID | 0.76 | 0.67 | 0.57 | 0.78 | 0.87 | 0.70 | 0.22 | 0.55 |
| BUD/GLY/FOR 320/18/9.6 µg BID | 0.67 | 0.76 | 0.69 | 0.62 | 0.38 | 0.62 | 0.49 | 0.70 |
| BUD/GLY/FOR 160/18/9.6 µg BID | 0.67 | 0.56 | 0.74 | 0.56 | 0.33 | 0.44 | 0.67 | 0.34 |
| FF/UMEC/VI 100/62.5/25 µg QD | 0.66 | 0.73 | 0.67 | 0.79 | 0.22 | 0.39 | 0.30 | 0.65 |
§ SUCRA = 1 when a treatment is considered to be the best, and SUCRA = 0 when a treatment is considered to be the worst; the SUCRA values were divided by quartiles where a score of 0–0.25 is the lowest quartile and 0.75–1.00 is the highest quartile. AECOPD: acute exacerbation of COPD; BDP: beclomethasone dipropionate; BID: bis in die, twice daily; BUD: budesonide; COPD: chronic obstructive pulmonary disease; CV: cardiovascular; FEV1: forced expiratory volume in the first second; FDC: fixed-dose combination; FF: fluticasone furoate; FOR: formoterol; GLY: glycopyrronium bromide or glycopyrrolate; QD: quaque die, once daily; SAE: serious adverse event; SGRQ: St. George’s Respiratory Questionnaire; SUCRA: surface under the cumulative ranking curve; TDI: transition dyspnea index; UMEC: umeclidinium bromide; VI: vilanterol.